Breaking News

Avacta, Daewoong Expand Affimer Alliance

To develop stem cell therapies for COVID-19 and future pandemic diseases.

By: Contract Pharma

Contract Pharma Staff

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, has expanded its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell Therapeutics to develop stem cell treatments incorporating Avacta’s neutralizing Affimer therapy for the treatment of seriously ill COVID-19 patients and to prepare to rapidly develop similar therapies for future pandemics. Respiratory diseases such as COVID-19 can cause serious damage to the lungs as a consequence of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters